FIG. 3.

Passively administered antibodies 2G12, 2F5, and 4E10 can contribute to in vivo complement lysis, but activity is low. Autologous lysis activities in patients with acute (triangles) and chronic (circles) infection (A) as well as in controller (closed squares) and noncontroller patients (open squares) (B). Means and 95% confidence intervals (error bars) from a multivariable linear regression model with robust variance estimator are shown (see Table S3 in the supplemental material). (C) Correlation analysis of MAb concentration in vivo and complement lysis activity. Week 12 plasma levels of MAb 2G12 (dots), 2F5 (triangles), and 4E10 (diamonds) do not correlate with matched plasma complement lysis activity against autologous virus. (D) Neither total lysis activity at week 12 nor the absolute increase in lysis activity from weeks 0 to 12 differs between controller and noncontroller patients. Means and 95% confidence intervals (error bars) are shown. (E and F) MAb-mediated neutralization in patient plasma at week 12 and complement lysis activity from the same time point against autologous (E) and heterologous (F) virus is not correlated. MAb-mediated 70% neutralization (NT₇₀) was determined previously using a TZM-bl cell-based neutralization assay (62).